CDC moves to update U.S. childhood immunization schedule after presidential memorandum

The CDC announced on January 5, 2026, that it signed a decision memorandum accepting recommendations to update U.S. childhood immunization practices following a presidential directive to review how peer developed countries structure vaccine schedules. The agency said it would move forward with implementation steps while emphasizing that insurance coverage without cost-sharing would continue for vaccines currently recommended by CDC.

In its release, the CDC described the review as a comparison across developed nations, examining vaccine recommendations, uptake, public trust, and scientific evidence. The assessment concluded that the United States recommends protection against more diseases and a higher total number of doses than peer countries, while not necessarily achieving higher vaccination rates than those nations.

Under the framework described, the CDC would continue organizing the schedule in three categories: vaccines recommended for all children, vaccines for certain high-risk groups, and vaccines offered based on shared clinical decision-making. The announcement listed vaccines that would remain in the “recommended for all children” category, including MMR, polio, DTaP components, Hib, pneumococcal, varicella, and HPV.

Federal health leaders framed the change as a trust-building effort, arguing that clearer recommendations and transparency could improve public confidence. The release also pointed to the need for continued research, including stronger evidence generation, as part of ongoing evaluation of vaccine benefits and risks.

Public-health experts have long noted that schedule debates can influence uptake and perceptions, making communication critical. As implementation proceeds, clinicians and parents are likely to look for detailed guidance on timing, eligibility, and how “shared decision-making” will work in practice across states and insurance plans.

What happens next

1. CDC coordination with state health agencies and medical groups on rollout details
2. Updated clinical guidance and educational materials for parents and clinicians
3. Monitoring for impacts on vaccination rates and vaccine-preventable disease risk